Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 88-92

  Jo, Mi Young ^a,b   Kim, Young Gyu ^e   Kim, Yonghyun ^a,b   Lee, Se Jeong ^a,b,d   Kim, Mi Hyun ^a,b   Joo, Kyeung Min ^d   Kim, Hyeon Ho ^b,c   Nam, Do Hyun ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Chungbuk National University College of Medicine   (South Korea)

Author keywords

Brain tumor; Combination therapy; Temozolomide; Vandetanib

Indexed keywords

ALKYLATING AGENT; CD31 ANTIGEN; CYCLINE; TEMOZOLOMIDE; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PARAMETERS; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICROVESSELS; PIPERIDINES; QUINAZOLINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861597049     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.868     Document Type: Article

References (24)

1. Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97: 6242-6244, 2000.
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
3. Stupp R, Hegi ME, Gilbert MR and Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25: 4127-4136, 2007. (Pubitemid 47492957)
4. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
5. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61, 1997. (Pubitemid 27273454)
6. Perry JR, Rizek P, Cashman R, Morrison M and Morrison T: Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the 'rescue' approach. Cancer 113: 2152-2157, 2008.
7. Kim JT, Kim JS, Ko KW, et al: Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16: 33-39, 2006.
8. Sandstrom M, Johansson M, Bergstrom P, Bergenheim AT and Henriksson R: Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 88: 1-9, 2008.
9. Ryan AJ and Wedge SR: ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 (Suppl 1): 6-13, 2005.
10. Gogas H, Polyzos A, Stavrinidis I, et al: Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 17: 1835-1841, 2006. (Pubitemid 44884061)
11. Kang SG, Kim JS, Park K, Groves MD and Nam DH: Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 15: 7-13, 2006.
12. Son MJ, Kim JS, Kim MH, et al: Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. Int J Oncol 28: 53-59, 2006.
13. Kong DS, Lee JI, Kim WS, et al: A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16: 1117-1121, 2006.
14. Agarwala SS and Kirkwood JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144-151, 2000.
15. Seiter K, Katragadda S, Ponce D, Rasul M and Ahmed N: Temozolomide and cisplatin in relapsed/refractory acute leukemia. J Hematol Oncol 2: 21, 2009.
16. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
17. Bao S, Wu Q, Sathornsumetee S, et al: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848, 2006. (Pubitemid 44299144)
18. Ono M, Izumi H, Yoshida S, et al: Angiogenesis as a new target for cancer treatment. Cancer Chemother Pharmacol 38: S78-S82, 1996.
19. Rich JN, Sathornsumetee S, Keir ST, et al: ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11: 8145-8157, 2005. (Pubitemid 41698759)
20. Kong DS, Kim MH, Jeon JW, et al: Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model. Mol Med Report 1: 343-346, 2008.
21. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793, 2004. (Pubitemid 38174017)
22. Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim AT and Henriksson R: The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 91: 1174-1180, 2004. (Pubitemid 39336259)
23. Yiin JJ, Hu B, Schornack PA, et al: ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther 9: 929-941, 2010.
24. Drappatz J, Norden AD, Wong ET, et al: Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78: 85-90, 2010.